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and cystic fibrosis (CF) (Gibson et al., 2017; Gotfried, 2004; 
Kawamura et al., 2017; Naderi et al., 2018; Pomares et al., 2018; 
Principi et al., 2015; Ramos and Criner, 2014) when used con-
tinuously. 
Our group has shown that AZM enhances epithelial barrier in-
tegrity in air-liquid interface (ALI) cultures and protects against 
bacterial infections (Asgrimsson et al., 2006; Halldorsson et al., 
2010). We have also shown that AZM treatment causes bron-
chial epithelial cells to differentiate towards an epidermal phe-
notype, along with forming multivesicular and lamellar bodies, 
and that saturated lipids conjugate to the AZM molecule when it 
enters the cell (Arason et al., 2019).
1  Introduction
Azithromycin (AZM) is a broad-spectrum macrolide antibi-
otic used to treat bacterial infections, mainly of the respiratory 
system. The antibacterial effects of AZM are mediated through 
binding to the 50S subunit of the bacterial ribosome (Champ-
ney and Burdine, 1998; Champney et al., 1998; Hansen et al., 
2002). However, there is increasing evidence that AZM has oth-
er pharmacological effects beyond its antibacterial activity, as 
it improves the health of patients suffering from chronic airway 
diseases such as chronic obstructive lung disease (COPD), bron-
chitis obliterans (BO), diffuse panbronchiolitis (DPB), asthma 
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Abstract
Azithromycin (AZM) is a broad-spectrum antibiotic widely used to treat infections. AZM also has been shown to have 
anti-inflammatory and immunomodulatory functions unrelated to its antibacterial activity that contribute to the effec-
tiveness of this drug in chronic respiratory diseases. The mechanisms behind these beneficial effects are not yet fully 
elucidated. We have previously shown that AZM enhances barrier integrity of bronchial epithelial cells and directs them 
towards epidermal differentiation. 
In this study, we analyzed the effect of AZM pre-treatment of human bronchial and alveolar derived cell lines on 
mechanical stress in a cyclical pressure air-liquid interface device (CPAD) that models the disruption of the epithelial 
barrier with increased inflammatory response in lung tissue, which is associated with ventilator-induced lung injury (VILI). 
Immunostaining and electron microscopy showed that barrier integrity of the epithelium was compromised by cyclically 
stressing the cells but maintained when cells had been pre-treated with AZM. Lamellar body formation was revealed in 
AZM pre-treated cells, possibly further supporting the barrier enhancing effects. RNA sequencing showed that the inflam-
matory response was attenuated by AZM treatment before cyclical stress. YKL-40, an emerging inflammatory marker, 
increased both due to cyclical stress and upon AZM treatment. These data confirm the usefulness of the CPAD to model 
ventilator-induced lung injury and suggest that AZM has barrier protective and immunomodulatory effects, attenuating 
the inflammatory response during mechanical stress, and might therefore be lung protective during mechanical ventilation. 
The model could be used to assess further drug candidates that influence barrier integrity and modulate inflammatory 
response. 
This is an Open Access article distributed under the terms of the Creative Commons 
Attribution 4.0 International license (http://creativecommons.org/licenses/by/4.0/), 
which permits unrestricted use, distribution and reproduction in any medium, provi-
ded the original work is appropriately cited. 
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screened bi-monthly for Mycoplasma contamination by way of 
Phenol/Chloroform extraction (all negative).
Both cell lines were cultured at the air-liquid interface (ALI) 
on 12 mm diameter Transwell™ filter inserts (Corning 0.4 µm) 
pre-coated with collagen IV (Sigma, C7521) for the VA10 cell line 
and huAEC coating solution (InSCREENEX, INS-SU-1018) for 
the hAELVi cell line. 200.000 cells were seeded per transwell fil-
ter. Cell lines were cultured for three weeks with or without 25 µg/ 
mL AZM (Zithromax, dissolved in 96% ethanol).
Trans-epithelial electrical resistance (TEER) was measured 
every other day. For this, medium was added to the apical side 
and resistance was measured using a Millicell ERS-2 Volt-Ohm 
meter.
Cyclical pressure ALI device
Both cell lines were cultured for 3 weeks with or without AZM 
supplementation. Half of the wells containing the cell layers were 
then placed in the CPAD for cyclical stressing for 24 h. The cy-
clical stress conditions were set according to our previous study 
(Joelsson et al., 2019) with peak pressure at 27 cm H2O and 
end-expiratory pressure at 5 cm H2O, creating a driving pressure 
of 22 cm H2O, with a respiratory rate of 16 breaths/min. The cy-
clical stress profile used in this study has a pressure difference 
that would produce ventilator induced lung injury (VILI) in clin-
ical circumstances. For the purposes of clarity, combinations of 
the following terms are used to describe the treatment conditions: 
no treatment = CON, Azithromycin pre-treatment = AZM, No 
stress = Static and 27 cm H2O cyclical stress = Stress. 
RNA sequencing and gene expression analysis
RNA was isolated from cells using TRIzol reagent (Invitrogen, 
Thermo Fisher Scientific) according to the manufacturer’s proto-
col. RNA sequencing was performed at BGI Genomics. We quan-
tified the RNA transcript expression with Kallisto version 0.45.0 
(Bray et al., 2016) using the Ensembl v94 reference transcriptome 
(Yates et al., 2016). Gene expression estimates were computed 
with the sleuth R package v0.30 (Pimentel et al., 2017). Gene set 
enrichment analysis was performed with GSEA software v4.0.1 
(Mootha et al., 2003; Subramanian et al., 2005). Pre-ranked gene 
lists were prepared by ordering the genes by expression differ-
ence significance (q-value multiplied with the sign of the log-
fold change) and tested for enrichment in the MSigDB hallmark 
gene set collection (Liberzon et al., 2015). Significantly differen-
tially expressed genes were uploaded to PANTHER gene ontolo-
gy classification system using a statistical overrepresentation test 
and biological process annotation data set.
All qPCRs were performed as previously reported (Joelsson et 
al., 2019). Primers used are listed in Tab. S11.
Protein analysis      
15 µg total protein was separated using a NuPAGE 4-12% Bis-
Tris gradient gel (Life Technologies, NP0323). Primary antibod-
ies used: mouse anti-chitinase-3-like protein 1 (YKL-40) (Mil-
lipore, MABC196); rabbit anti-IĸBa (Cell Signaling Technolo-
Acute respiratory distress syndrome (ARDS) is a serious con-
dition of severe respiratory failure with high mortality commonly 
encountered amongst critically ill patients in intensive care units 
(ICUs). ARDS is characterized by alveolar-capillary barrier fail-
ure in the distal bronchi and alveoli, and the expansion of resident 
macrophages that release signals prompting a response from in-
flammatory cells in the nearby pulmonary vasculature. This is fol-
lowed by fluid accumulation or a complete collapse of the alveo-
lar sacs, resulting in loss of gas exchange and inadequate aeration 
(Thompson et al., 2017). During mechanical ventilation (MV), air 
is forced into the lungs, which can lead to damage of the lung 
epithelium due to mechanical stress and ultimately, in some cas-
es, ventilator-induced lung injury (VILI) (Slutsky and Ranieri, 
2013). MV can therefore exacerbate ARDS by causing further 
lung injury. 
Clinical research on VILI/ARDS is challenging due to the high-
risk nature of invasive diagnostic procedures in patients with such 
severe respiratory failure. Access to patient lung samples is there-
fore limited, and although there are numerous in vitro stress-in-
ducing lung models (Huh, 2015; Karadottir et al., 2015; Ressler et 
al., 2000; Shiomi et al., 2011; Yu and Li, 2017; Zhao et al., 2014), 
they are restricted mimics of events in human lungs during ARDS 
or VILI because of the cyclical nature of MV. 
In a recent paper, we described a device referred to as a cyclical 
pressure air-liquid interface device (CPAD) (Joelsson et al., 2019) 
in which cultures of human lung cells cultured at ALI are exposed 
to cyclical pressure to model MV. This device aims to replace an-
imal experiments on MV and VILI with a human-relevant system 
that allows mechanistic investigation. 
In this work, we use the CPAD to cyclically stress bronchial 
and alveolar cell lines in ALI cultures and show that, whereas un-
treated cells present a disrupted phenotype following mechanical 
strain, AZM maintains the barrier integrity in both cell lines. We 
observed vesicle and lamellar body formations in CPAD stressed 
cells which was exaggerated in AZM pre-treated cells. We al-
so show that AZM pre-treatment attenuates the inflammatory re-
sponse in CPAD stressed cells. 
2  Methods
Cell culture
Two cell lines were used in this research. VA10 (Halldorsson et 
al., 2007) was cultured in animal origin-free Bronchial/Trache-
al Epithelial Cell Medium (Cell Applications, 511A-500) sup-
plemented with retinoic acid (Cell Applications, 511-RA), and 
hAELVi (Kuehn et al., 2016) was cultured in Human Airway Ep-
ithelial Cell Medium (InSCREENEX, INS-ME-1013). Both cell 
lines were supplemented with Penicillin (20 IU/mL)/Strepto-
mycin (20 µg/mL) (Life Technologies, 15140122). The cell cul-
ture medium used for cell differentiation of VA10 cells in ALI 
cultures was Dulbecco’s Modified Eagle Medium F-12 Nutri-
ent Mixture (DMEM/F12, Thermo Fisher Scientific) which was 
supplemented with 2% Ultroser G (PALL). All cell cultures were 
1 doi:10.14573/altex.2001271s
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gy, 9242S) and rabbit anti-β-tubulin (Cell Signaling Technology, 
2128). Secondary antibodies conjugated with horse radish peroxi-
dase (HRP) (goat anti-rabbit IgG, Sigma, A0545; goat anti-mouse 
IgG, Millipore, AP181P) were used. Conditioned medium from 
cell culture was analyzed by sandwich enzyme-linked immuno-
sorbent assays (ELISAs) using an interleukin 8 (IL-8) assay kit 
(Peprotech, UK).
Confocal imaging
Samples were fixed in formalin and embedded in paraffin, then 
sectioned and immunostained. Antibodies used were rabbit an-
ti-NFĸB p65 (Santa Cruz Biotechnology, sc-372), mouse an-
ti-E-Cadherin (BD Transduction Laboratories, 610182), mouse 
anti-chitinase-3-like protein 1 (YKL-40) (Millipore, MAB196), 
rabbit anti-surfactant protein B (Abcam, ab40876). Appropriate 
secondary antibodies were purchased from ThermoFisher. Count-
er staining was done using DAPI (1:5000) (Sigma-Aldrich). 
Phalloidin (1:40) used for actin staining was from ThermoFish-
er (A22283). A list of secondary antibodies used is provided in 
Table S21. Immunofluorescence was imaged using an Olympus 
FV1200 confocal microscope (Olympus, Tokyo, Japan). Pixel in-
tensity quantifications were calculated with ImageJ.
Transmission electron microscopy
Cell layers were fixed with 2.5% glutaraldehyde for 20 min fol-
lowed by washing. Cells were dehydrated and then embedded in 
resin. 100 nm sections were cut by ultramicrotome. Sections were 
stained with lead citrate and imaged using a JEM-1400PLUS PL 
Transmission Electron Microscope. 
Statistical analysis
For determining statistical significance analysis, a two-way 
ANOVA was utilized and calculated using GraphPad Prism 8.0. 
Error bars represent the standard deviation (SD). 
3  Results
3.1  Azithromycin pre-treatment maintains 
barrier integrity in cyclically stressed bronchial 
and alveolar lung epithelial cell lines
VA10 bronchial cells
VA10 bronchial cell lines exhibited increased TEER when treat-
ed with AZM (Fig. S1A1) as reported previously by (Arason et al., 
Fig. 1A: Azithromycin pre-treatment 
maintains barrier integrity in cyclically 
stressed VA10 cell layers
Confocal immunofluorescent images of 
ALI-cultured VA10 cell layers with/without 
AZM treatment (CON/AZM) in static or 
stress conditions (Static/Stress) for  
21 days. i) Actin stained with phalloidin 
(green); ii) E-Cadherin (green) and 
nuclei stained with DAPI (blue). Images 
are representative of 3 independent 
experiments (N = 3). Scale bar is 100 µm.  
iii) Electron microscopic images of ALI-
cultured VA10 cell layers with/without 
AZM treatment (CON/AZM) in static or 
stress conditions (Static/Stress). Images 
are representative of 3 independent 
experiments (N = 3). Scale bars are 10 µm 
for top images, 2 µm for middle images and 
1 µm for lower images. 
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1Aiii). When the cell layer was cyclically stressed (CON/Stress), 
it started to form vesicles, and a disruption of the polarized uni-
form phenotype was detected with wider gaps between cells 
(Fig. 1Aiii) (Joelsson et al., 2019). When the cells were treated 
with AZM (AZM/Static) for the duration of the ALI culture, the 
cell layer became thicker (Arason et al., 2019), and vesicles and 
lamellar bodies (LB) appeared (Fig. 1Aiii). When AZM pre-treat-
ed cell layers were stressed (AZM/Stress), the vesicles and LBs 
along with the thicker layer were observed, but not the disrupted 
phenotype (Fig. 1Aiii).
hAELVi alveolar cells
The recently established hAELVi cell line (Kuehn et al., 2016) 
was used to analyze the effect of AZM treatment and cyclical 
stress on an alveolar-derived cell line. AZM treatment resulted in 
no significant difference in TEER measurements (Fig. S1B1). 
Phalloidin-stained hAELVi cell layers viewed by confocal mi-
croscopy showed uniform tube-like structures within the cell lay-
er that were reduced with cyclical stress as the structures were 
2019). Actin staining with phalloidin of ALI-cultured VA10 cells 
displayed a grid-like formation (Fig. 1Ai, upper left). Cyclically 
stressing VA10 cell layers resulted in a disruption of this structure 
along with aggregation of actin filaments (Fig. 1Ai, upper right). 
AZM treatment of VA10 cell layers showed the same grid-like 
form of the lung epithelial layer as seen in the control cells (Fig. 
1Ai, lower left). Importantly, AZM treatment consistently resulted 
in larger cells, possibly due to changes in lipid metabolism, as seen 
previously in VA10 cells (Arason et al., 2019). Cyclically stress-
ing AZM pre-treated cell layers maintained this structure without 
aggregation or disruption of actin (Fig. 1Ai, lower right). 
Similar effects were observed when cell layers were stained 
for E-cadherin: The E-cadherin signal was diminished compared 
to controls in cyclically stressed cells (CON/Stress), but AZM 
pre-treatment retained the unstressed control phenotype in both 
the unstressed (AZM/Static) and cyclically stressed cell layers 
(AZM/Stress) (Fig. 1Aii). 
When viewed in the electron microscope, VA10 ALI cultured 
cells (CON/Static) presented a polarized uniform cell layer (Fig. 
Fig. 1B: Azithromycin pre-treatment 
maintains barrier integrity in cyclically 
stressed hAELVi cell layers 
Confocal immunofluorescent images 
of ALI-cultured hAELVi cell layers with/
without AZM treatment (CON/AZM) in 
static or stress conditions (Static/Stress) 
for 21 days. i) Actin stained with phalloidin 
(green); ii) E-Cadherin (green) and 
nuclei stained with DAPI (blue). Images 
are representative of 3 independent 
experiments (N = 3). Scale bar is 100 
µm. iii) Electron microscopic images of 
ALI-cultured VA10 cell layers with/without 
AZM treatment (CON/AZM) in static or 
stress conditions (Static/Stress). Images 
are representative of 3 independent 
experiments (N = 3). Scale bars are 10 µm 
for top images, 2 µm for middle images  
and 1 µm for lower images. 
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duction by AZM pre-treatment alone, but with no further exacer-
bations when cyclically stressed (Fig. 2B).         
3.2  AZM attenuates inflammatory  
response in mechanically stressed VA10 cell layers –  
RNA sequencing analysis
We have previously shown that TNFα and IL8 expression was in-
creased in the CPAD model using bronchial epithelial lung cell 
lines (Joelsson et al., 2019), and it has been reported that AZM 
treatment has anti-inflammatory effects in airway epithelial cells 
(Cigana et al., 2006). Accordingly, we analyzed the effects of 
AZM treatment on cyclically stressed epithelial cells in the CPAD 
system. For this purpose, we compared RNA sequenced VA10 
cells that had been cultured at ALI for three weeks with or with-
out AZM treatment, then subjected to 27 cm H2O stress for 24 h 
in the CPAD or cultured in static conditions. 
Running a gene set enrichment analysis (GSEA) (Mootha et al., 
2003; Subramanian et al., 2005) on the cells exposed to the two ex-
perimental conditions showed that cyclically stressing the untreated 
cells resulted in considerable enrichment of genes connected to in-
flammatory-associated gene sets (Fig. 3A). The pathways with the 
highest normalized enrichment scores (NES) showed significant 
positive correlation to interferon (IFN)α response, IFNγ response, 
TNFα signaling via NFĸB, inflammatory response, complement 
system response, and cholesterol homeostasis gene sets (Fig. 3A). 
GSEA of AZM pre-treated cells exposed to CPAD stress (AZM/
Stress) compared to CON/Static, however, showed that some dif-
ferent gene sets were involved in the highest NES scores, show-
ing positive correlation with oxidative phosphorylation, cho-
lesterol homeostasis, MTORC signaling, IFNα response, MYC 
target V1 and protein secretion gene sets (Fig. 3B and Fig. S21). 
Some pathways, such as the IFNα gene pathway, were enriched 
in both conditions, but the NES for the inflammation related 
compressed (Fig. 1Bi, upper and Fig. 1Biii). AZM pre-treatment 
of the hAELVi cell line presented a phenotype similar to the un-
treated counterparts and remained so when cyclically stressed 
(Fig. 1Bi, lower). 
E-Cadherin staining revealed a clear loss of signal in the 
stressed cells, but grid formation was maintained in AZM 
pre-treated cells (Fig. 1Bii). 
The hollow, tube-like structures of the hAELVi cell layers 
(CON/Static) were also visible when viewed in the electron mi-
croscope (Fig. 1Biii). These structures were more compacted 
when cells were exposed to cyclical stress (CON/Stress). Fur-
thermore, LBs were more visible in cyclically stressed cells com-
pared to unstressed cells (Fig. 1Biii). AZM treatment of hAELVi 
cell layers (AZM/Static) resulted in similar tube-like structures 
as the untreated cell layers, and LBs started forming (Fig. 1Biii). 
Cyclically stressing AZM pre-treated cell layers (AZM/Stress) 
flattened the layer and LBs were more prevalent (Fig. 1Biii). 
Surfactant production
To check whether the observed vesicle formation was associat-
ed with surfactant production and because of its connection as a 
VILI/ARDS associated biomarker (Blondonnet et al., 2016; Mey-
er and Christie, 2013), we stained the cell layers for surfactant 
protein B (SFPB). 
In VA10 cell layers there was a marked increase in SFPB 
expression under cyclical stress (Fig. 2A, upper). AZM treat-
ment of the VA10 cell layers did not result in a pronounced SFPB 
increase but interestingly, pre-treating the cell layers with AZM 
and then cyclically stressing the cells did not result in the no-
ticeable increases in SFPB production seen in the untreated cell 
layers (Fig. 2A). 
The same tests were done on the hAELVi cell line and similar 
results were seen, with the addition of an increase in SFPB pro-
Fig. 2: Mechanically induced expression 
of surfactant protein B (SFPB) is 
attenuated in azithromycin pre-treated  
cell layers
Confocal immunofluorescent images of 
ALI-cultured A) VA10  
and B) hAELVi cell layers with/without AZM 
treatment  
(CON/AZM) in static or stress conditions 
(Static/Stress) for 21 days stained for SFPB 
and nuclei stained with DAPI (insets). 
Images  
are representative of 3 independent 
experiments (N = 3).
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Fig. 3: Pre-treatment with 
azithromycin results in an 
attenuated inflammatory 
response in mechanically 
stressed VA10 cell layers – 
RNA sequencing analysis
Significant (nominal p-value 
≤ 0.05) gene set enrichment 
plots that resulted from 
comparing conditions are 
shown:  
A) CON/Static vs CON/
Stress;  
B) CON/Static vs AZM/
Stress; 
Joelsson et al.
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C) CON/Stress vs AZM/
Stress;  
D) CON/Static vs AZM/Static; 
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E) AZM/Static vs. AZM/
Stress. Positive correlations 
are reflected as high 
normalized enrichment 
scores (NES).
Tab. 1: List of over-represented gene ontology (GO) groups in A) CON/Static vs CON/Stress and B) CON/Static vs AZM/Stress 
pretreated VA10 cell layers  
RNA sequencing data was uploaded into the Panther gene ontology database. Only genes with a q-value of ≤ 0.05 and a fold change  
of ≥ 2 were uploaded. The 33 Panther GO categories with the highest fold enrichment are shown. 
A) CON/Static vs CON/Stress
GO biological process complete Fold enrichment Raw P-value
regulation of type III interferon production (GO:0034344) 65.82 6.42E-05
wound healing involved in inflammatory response (GO:0002246) 32.91 2.61E-04
neural crest cell migration involved in autonomic nervous system development (GO:1901166) 32.91 2.61E-04
ISG15-protein conjugation (GO:0032020) 32.91 2.61E-04
detection of virus (GO:0009597) 32.91 2.61E-04
cytoplasmic pattern recognition receptor signaling pathway in response to virus (GO:0039528) 32.91 2.61E-04
regulation of ribonuclease activity (GO:0060700) 29.25 3.16E-05
inflammatory response to wounding (GO:0090594) 28.21 3.69E-04
positive regulation of RIG-I signaling pathway (GO:1900246) 21.94 6.61E-04
positive regulation of blood vessel endothelial cell proliferation involved in sprouting 21.94 6.61E-04 
angiogenesis (GO:1903589) 
positive regulation of T cell apoptotic process (GO:0070234) 21.94 9.38E-06
type I interferon signaling pathway (GO:0060337) 21.61 5.61E-21
cellular response to type I interferon (GO:0071357) 21.61 5.61E-21
response to type I interferon (GO:0034340) 21.03 1.19E-21
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A) CON/Static vs CON/Stress
GO biological process complete Fold enrichment Raw P-value
negative regulation of viral genome replication (GO:0045071) 20.08 6.47E-17
response to interferon-alpha (GO:0035455) 19.20 3.04E-07
positive regulation of T cell differentiation in thymus (GO:0033089) 17.95 1.07E-03
positive regulation of lymphocyte apoptotic process (GO:0070230) 17.32 2.45E-05
response to interferon-beta (GO:0035456) 15.89 9.06E-07
negative regulation of viral life cycle (GO:1903901) 15.86 5.89E-17
positive regulation of interferon-alpha production (GO:0032727) 15.80 5.76E-06
regulation of interferon-alpha production (GO:0032647) 14.86 1.33E-06
cellular response to exogenous dsRNA (GO:0071360) 14.63 2.91E-04
positive regulation of monocyte chemotaxis (GO:0090026) 14.63 2.91E-04
negative regulation of viral process (GO:0048525) 14.34 1.01E-17
defense response to virus (GO:0051607) 13.50 1.65E-30
regulation of viral genome replication (GO:0045069) 13.30 5.89E-15
cellular response to interferon-beta (GO:0035458) 13.16 4.13E-04
positive regulation of cell migration involved in sprouting angiogenesis (GO:0090050) 12.54 4.86E-04
regulation of nuclease activity (GO:0032069) 11.97 5.67E-04
fibrinolysis (GO:0042730) 11.97 5.67E-04
pyrimidine nucleoside catabolic process (GO:0046135) 11.45 6.58E-04
cellular response to dsRNA (GO:0071359) 11.45 6.58E-04
B) CON/Static vs AZM/Stress 
GO biological process complete Fold enrichment Raw P value
cholesterol biosynthetic process via lathosterol (GO:0033490) 21.63 1.19E-03
cholesterol biosynthetic process via desmosterol (GO:0033489) 21.63 1.19E-03
smooth muscle adaptation (GO:0014805) 21.63 1.19E-03
foam cell differentiation (GO:0090077) 16.48 3.42E-04
macrophage derived foam cell differentiation (GO:0010742) 16.48 3.42E-04
low-density lipoprotein particle clearance (GO:0034383) 13.22 1.11E-08
positive regulation of ryanodine-sensitive calcium-release channel activity (GO:0060316) 12.82 7.02E-04
skin morphogenesis (GO:0043589) 12.82 7.02E-04
chemical homeostasis within a tissue (GO:0048875) 11.09 2.48E-04
cholesterol biosynthetic process (GO:0006695) 10.99 4.63E-11
sterol biosynthetic process (GO:0016126) 10.82 3.51E-12
secondary alcohol biosynthetic process (GO:1902653) 10.73 6.15E-11
membrane raft assembly (GO:0001765) 10.49 1.27E-03
N-acetylneuraminate metabolic process (GO:0006054) 10.49 1.27E-03
surfactant homeostasis (GO:0043129) 10.49 1.27E-03
regulation of cholesterol biosynthetic process (GO:0045540) 10.06 5.10E-10
regulation of sterol biosynthetic process (GO:0106118) 10.06 5.10E-10
negative regulation of protein homooligomerization (GO:0032463) 9.61 1.65E-03
sequestering of metal ion (GO:0051238) 9.61 1.65E-03
hemidesmosome assembly (GO:0031581) 9.61 1.65E-03
phagosome acidification (GO:0090383) 9.27 2.72E-06
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gene sets was considerably higher for the CON/Static cells, i.e., 
3.44 compared to 2.27 in that case (Fig. S21). 
When comparing RNA sequencing of CON/Stress vs AZM/
Stress, we observed that inflammation related pathways were sig-
nificantly negatively correlated (Fig. 3C). Several of the pathways 
that were upregulated because of stress were downregulated when 
cells were AZM pre-treated (Fig. 3A,C). 
The effect of AZM treatment alone was also explored. The posi-
tively correlated gene sets were not associated with inflammation, 
but there was a high negative correlation to inflammatory response 
and TNFα signaling via NFĸB (Fig. 3D). 
Lastly, we compared AZM/Static vs AZM/Stress. The inflam-
matory response was present, but the NES was considerably lower 
compared to CON/Static vs CON/Stress. Also, fewer inflammato-
ry related gene sets were significantly enriched (Fig. 3E). 
Exploring the IFNα pathway, we set up a heat map showing 24 
of the most significantly differentially expressed genes in the path-
way (Fig. S31). This clearly shows the attenuating effect of AZM on 
gene expression.
To further investigate the gene enrichment patterns of the two 
conditions, we uploaded statistically significantly (P ≤ 0.05) dif-
ferentially expressed genes with at least two-fold upregulation 
into the PANTHER gene ontology (GO) classification system 
(Mi et al., 2017). The outcome was two very different GO biologi-
cal process analyses. Cyclical stress of untreated cell layers (CON/
Stress) resulted in enrichment of inflammation-linked GO catego-
ries (Tab. 1A). Cyclically stressing AZM pre-treated cells (AZM/
Stress) resulted in the top enriched GO categories being associated 
with lipid metabolism and skin barrier (Tab. 1B). 
As the GO analyses indicated prominent type-I interferon path-
way activity (fold enrichment of 21.61 and raw P-value of 5.6E-21) 
in the CON/Stress cell layer, we looked up the genes that were en-
riched in our gene set and saw that the genes involved were less dif-
ferentially expressed in the AZM/Stress setting (Tab. 2). AZM-me-
diated immunomodulation was also detected when important im-
munity markers (cytokines/chemokines, toll-like receptors, matrix 
B) CON/Static vs AZM/Stress 
GO biological process complete Fold enrichment Raw P value
intracellular cholesterol transport (GO:0032367) 9.01 5.43E-04
regulation of water loss via skin (GO:0033561) 8.87 1.28E-05
establishment of skin barrier (GO:0061436) 8.78 4.79E-05
regulation of cholesterol metabolic process (GO:0090181) 8.76 2.16E-10
ceramide catabolic process (GO:0046514) 8.65 1.80E-04
intracellular sterol transport (GO:0032366) 8.48 6.83E-04
cornification (GO:0070268) 8.24 1.01E-17
transferrin transport (GO:0033572) 8.01 2.30E-06
positive regulation of steroid biosynthetic process (GO:0010893) 8.01 8.49E-04
plasma lipoprotein particle clearance (GO:0034381) 7.74 9.57E-07
positive regulation of histone deacetylation (GO:0031065) 7.59 1.04E-03
cholesterol efflux (GO:0033344) 7.52 3.41E-04
Tab. 2: Genes of the GO biological process “Response to 
type I interferon” differentially expressed in the  
CON/Stress vs AZM/Stress pretreated VA10 cell layers 
RNA sequencing data was uploaded into the Panther gene 
ontology database. Only genes with a q-value of ≤ 0.05  
and a fold change of ≥ 2 were uploaded.
Mapped Ids Gene name CON AZM
  Fold change
ENSG00000185507 IRF7 21.81 13.43
ENSG00000172183 ISG20 19.11 15.96
ENSG00000157601 MX1 15.35 2.06
ENSG00000183486 MX2 11.94 2.49
ENSG00000089127 AC004551.1 11.18 3.70
ENSG00000101347 SAMHD1 10.37 0.12
ENSG00000111335 OAS2 9.71 2.19
ENSG00000130813 C19orf66 9.56 1.60
ENSG00000134321 RSAD2 8.92 4.99
ENSG00000185745 IFIT1 8.33 5.18
ENSG00000067066 SP100 7.81 1.34
ENSG00000187608 ISG15 6.13 2.99
ENSG00000115415 STAT1 5.25 1.80
ENSG00000119917 IFIT3 4.73 5.42
ENSG00000111331 OAS3 4.16 1.51
ENSG00000135114 OASL 3.96 1.21
ENSG00000068079 IFI35 3.30 1.82
ENSG00000126709 IFI6 3.09 2.35
ENSG00000165949 IFI27 3.05 2.61
ENSG00000132530 XAF1 2.88 1.35
ENSG00000185885 IFITM1 2.63 3.02
ENSG00000172936 MYD88 2.52 1.29
ENSG00000119922 IFIT2 1.95 3.28
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metalloproteases and TNF super family) were tested in the data-
sets of both conditions (Tab. 3). Only significantly differentially ex-
pressed genes are shown (P ≤ 0.05). CON/Stress cell layers tend-
ed to show considerable differential expression of selected immune 
genes, whereas AZM/Stress cell layers showed fewer differentially 
expressed genes (Tab. 3).        
3.3  AZM attenuates stress-induced 
inflammatory response in bronchial epithelial 
cell layers – immunostaining analysis
As the gene enrichment analysis showed high enrichment 
scores for TNFα signaling via NFĸB, we analyzed the effects of 
AZM-pretreatment on NFĸB localization in VA10 cells. Cell lay-
ers were immunostained for NFĸB and viewed using a confo-
cal microscope. Using the co-localization feature of the Olym-
pus fluoview software, we observed that NFκB translocation to 
the nucleus was increased in CON/Stress cell layers, compared 
to CON/Static cell layers (Fig. 4A, upper). Compared to CON/
Stress cell layers, the NFĸB nuclear translocation was attenuated 
in AZM/Stress conditions (Fig. 4A, lower). 
As NFĸB nucleus translocation is usually preceded by a break-
down of IĸB, we investigated the expression of IĸB. Western blot-
ting revealed no changes in IĸB protein level, indicating non-ca-
nonical NFĸB pathway activation (Sun, 2017) (Fig. S41). 
On transcriptional level, we had seen that the expression of 
pro-inflammatory cytokine CXCL8 was decreased by AZM 
pre-treatment (AZM/Static), but significantly increased upon me-
chanically stressing the cells (CON/Stress). The combined ef-
fect of AZM pre-treatment and mechanically stressing the cells 
(AZM/Stress) resulted in non-significant changes (Fig. 4B). This 
was substantiated on a protein level by detection of IL-8 release 
by ELISA, which showed the same pattern as the gene expression 
(Fig. 4C).        
3.4  YKL-40 is modulated in both cyclically stressed 
and AZM treated bronchial lung cell layers
As YKL-40 is an emerging inflammatory marker (Dela Cruz et 
al., 2012; Libreros et al., 2013) that has been implicated in im-
munomodulation (Kastrup, 2012; Ling and Recklies, 2004) and 
tissue remodeling (Lee et al., 2011), and as a follow up to our 
previous study (Joelsson et al., 2019) showing increased expres-
sion of YKL-40 due to mechanical stress in bronchial cell lay-
ers, we analyzed the effects of AZM pre-treatment on YKL-40. 
YKL-40 immunofluorescent staining was increased upon me-
chanical stress in VA10 cell layers (CON/Stress) compared to 
CON/Static (Fig. 5A, upper). AZM pretreatment also increased 
YKL-40 protein staining (AZM/Static); this was not further in-
creased by mechanical stress (AZM/Stress) (Fig. 5A, lower). 
Pixel intensity quantifications are shown in Figure S51. In line, 
Western blots in VA10 ALI cultured cells showed an increase in 
YKL-40 protein in CON/Stress compared to CON/Static condi-
tions, as we had shown previously (Joelsson et al., 2019). The 
increase in YKL-40 protein was more pronounced in AZM/Stat-
ic cells with no further increase in AZM/Stress cells (Fig. 5B 
and Fig. S61). Immunohistochemical staining of YKL-40 in un-
treated cells, and in AZM pre-treated cells, showed an increase 
Tab. 3: Genes related to the immune response differentially 
expressed in the CON/Stress vs AZM/Stress pretreated VA10 
cell layers 
RNA sequencing data was uploaded into the Panther gene 
ontology database. Only genes with a q-value of ≤ 0.05 and a fold 
change of ≥ 2 were uploaded. 
CON/Static vs CON/Stress CON/Static vs AZM/ Stress
Cytokines/Chemokines
CXCL11  CXCL14 
CXCL10  CXCL17 
CXCL9  IL1RN 
CXCL16  IL1B 
CXCL17  IL18 
CXCL1  IL7R 
CXCL5  IL6ST 
IL36G   
IL1RN   
IL1A   
IL1B   
IL22RA1   
IL18   
IL20RB   
IL1R1   
IL1RL1   
IL20RA   
IL7      
Toll-like receptors
TLR3      
Matrix metalloproteases – Inflammatory mediators
MMP10  MMP7 
MMP13  MMP28 
MMP3   
MMP2   
MMP14   
MMP15   
MMP7      
TNFSF13B  TNFAIP2 
TNFSF10  TNFSF14 
TNFRSF10A  TNFRSF21 
TNFAIP1   
TNFRSF21   
TNFRSF10C     
Log2 of Fold change
4                                                                  -4
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blood vessels are overly active, resulting in excessive inflammato-
ry responses (Slutsky and Ranieri, 2013). The immunomodulatory 
effects of macrolides are gaining interest in this respect (Zimmer-
mann et al., 2018). AZM in particular has been linked to reducing 
the production of pro-inflammatory cytokines and promoting the 
resolution of chronic inflammation (Cramer et al., 2017). 
Alveolar and bronchial lung cell layers subjected to CPAD 
stress showed a disrupted barrier, characterized by loss of grid-
like formation with aggregated and disorganized actin fibers along 
with a reduction of important junctional proteins, i.e., E-cadherin. 
We observed that upon pre-treatment with AZM, barrier integrity 
was maintained during cyclical stress in the CPAD. An increase 
in vesicle and lamellar body formations was seen when untreat-
ed cells were mechanically stressed. As expected (Arason et al., 
2019), AZM pre-treatment already increased lamellar body for-
mation, which is associated with barrier integrity in the epidermis. 
When AZM pre-treated cells then were stressed in the CPAD, an 
in YKL-40 expression along with a thickening of the cell layer 
(Fig. 5D), as seen in AZM treated cell layers before (Arason et 
al., 2019).
The expression of CHI3L1 (gene for YKL-40) increased in 
CON/Stress as well as AZM/Static cells (Fig. 5C). However, in 
comparison, the gene expression in AZM/Stress cells was much 
higher, indicating a co-operative effect. CHI3L1 differential ex-
pression was confirmed by RNA sequencing. Expression was in-
creased 1.8-fold in CON/Stress versus CON/Static conditions and 
10.2-fold in AZM/Stress versus CON/Static conditions (Fig 5E).
4  Discussion
Clinically, barrier failure of the epithelium is associated with in-
flammation and excessive cytokine signaling, aggravating the clin-
ical symptoms of the patient, as immune cells from the surrounding 
Fig. 4: Azithromycin 
pretreatment attenuates 
stress-induced 
inflammatory response  
in VA10 bronchial  
cell layers
ALI-cultured VA10 cell layers 
with/without AZM treatment 
(CON/AZM) in static or stress 
conditions (Static/Stress)  
for 21 days.  
A) Confocal immuno-
fluorescent images stained 
for NFĸB translocation to 
DAPI-stained nuclei. Only 
co-localizations of DAPI and 
NFĸB are shown using the 
co-localization feature of the 
Olympus fluoview software; 
z-stacks were merged; insets 
show DAPI-stained nuclei. 
Representative images of  
3 independent experiments 
(N = 3). Scale bar is 100 µm.  
B) CXCL8 expression  
(N = 5; **, P ≤ 0.01) and  
C) IL-8 protein measured by 
ELISA (N = 3, *, P ≤ 0.05).
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tor, GSEA showed a strong positive correlation to many im-
mune-related gene sets. However, GSEA in AZM/Stress cell lay-
ers showed considerably lower NES in the same immune related 
gene sets, indicating an attenuated inflammation response. When 
we compared CON/Stress cells with AZM/Stress cells, we ob-
served that AZM treatment resulted in negative correlation with 
a number of inflammation related pathways. In fact, inflamma-
tory response gene sets, along with TNFα signaling via NFĸB, 
were negatively correlated when AZM pre-treatment was the on-
ly factor. A similar effect was observed when differentially ex-
pressed genes were analyzed by PANTHER, another GO data-
base. Overrepresented inflammation and immune related GO cat-
egories seen in CON/Stress cells were not seen in AZM/Stress 
cells, being replaced by fatty acid metabolism- and barrier-related 
GO categories. When immune markers, i.e., cytokines/chemok-
ines, toll-like receptors, matrix metalloproteases and TNF super 
family were checked in the RNA sequencing data, the number of 
genes significantly differentially expressed because of cyclical 
stress was markedly reduced when cells had been pre-treated with 
AZM, indicating a dampening of the immune response.
AZM pre-treatment of bronchial lung epithelial cells result-
ed in significant downregulation of TNF and CXCL8, key effec-
tors of inflammatory response (Lawrence, 2009). In this work, we 
exaggerated lamellar body formation response was observed, in-
dicating that lamellar body formation under pressure might be a 
protective response to injury. With the addition of AZM, this re-
sponse was augmented to the extent that a functional barrier was 
maintained. 
Importantly, we saw that cyclical stress induces SFPB expres-
sion both in untreated VA10 and hAELVi cell lines. In line, we re-
ported earlier that SFPB gene expression both in untreated VA10 
cells in response to stress in the CPAD (Joelsson et al., 2019). For 
the hAELVi cell line, this could indicate a sub-population of alve-
olar type II cells within the cell culture. In these cells, the AZM 
pre-treatment resulted in slightly increased SFPB expression, 
possibly due to activation of these type II cells, but no further in-
crease was detected after cyclically stressing the cells. Surfactant 
production has been linked to prognosis in pulmonary diseases 
(Delgado et al., 2015; Han and Mallampalli, 2015). As no fur-
ther surfactant production was seen in AZM-treated mechanical-
ly stressed cells, we postulate that this might indicate a protec-
tive mechanism where surfactant production is not as readily trig-
gered by injury in AZM-treated cells.
Upon analyzing RNA sequencing data of the bronchial VA10 
cells, where we compared the gene expression profiles of all the 
conditions tested, we found that when stress was the only fac-
Fig. 5: YKL-40 expression is 
modulated in both stress-
induced and azithromycin-
treated bronchial cell layers
ALI-cultured VA10 cell layers 
with/without AZM treatment 
(CON/AZM) in static or stress 
conditions (Static/Stress) 
for 21 days. A) Confocal 
images stained for YKL-40. 
Representative images of  
3 independent experiments 
are shown (N = 3). B) Western 
blot analysis for YKL-40. 
Representative images of  
3 independent experiments 
are shown (N = 3). β-tubulin 
shown as house-keeping gene. 
C) Gene expression of CHI3L1 
determined by RT-qPCR (N = 9; 
*, P ≤ 0.05; ****, P≤ 0.0001).  
D) Immunohistochemical 
staining of cell layers with 
YKL-40; counterstained with 
hematoxylin. Representative 
images of 3 independent 
experiments are shown.  
Scale bar is 100 µm.  
E) Gene expression of CHI3L1 
determined by RNA sequencing. 
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et al., 2019). The information provided in this paper may be an 
important step towards understanding the biological pathways 
that underlie the effects of AZM and might be utilized to develop 
drugs without antibacterial activity that influence barrier integri-
ty and modulate inflammatory response. These could be screened 
and characterized in the CPAD model and compared to AZM to 
reduce and replace animal experiments. 
Overall, the findings of this study show that AZM pre-treat-
ment maintains barrier integrity in mechanically stressed bronchi-
al and alveolar cell layers and shows a robust anti-inflammatory 
modulation in bronchial cell layers.
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